Sai Hong Ignatius Ou

Summary

Affiliation: University of California
Country: USA

Publications

  1. doi HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo- and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib
    Sai Hong Ignatius Ou
    Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, California Electronic address
    J Thorac Oncol . 2016
  2. doi Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping
    Sai Hong Ignatius Ou
    Chao Family Comprehensive Cancer Center, Department of Medicine, Division of Hematology Oncology, University of California Irvine School of Medicine, Orange, California Electronic address
    J Thorac Oncol 12:137-140. 2017
  3. doi High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression
    Sai Hong Ignatius Ou
    Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, CA 92868, USA Electronic address
    Lung Cancer 98:59-61. 2016
  4. doi Alectinib induced CNS radiation necrosis in an ALK+NSCLC patient with a remote (7 years) history of brain radiation
    Sai Hong Ignatius Ou
    Division of Hematology Oncology, Department of Medicine, University of California Irvine School of Medicine, Orange, CA 92868, United States Chao Family Comprehensive Cancer Center, Orange, CA 92868, United States Electronic address
    Lung Cancer 96:15-8. 2016
  5. doi Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study
    Sai Hong Ignatius Ou
    Sai Hong Ignatius Ou, University of California Irvine School of Medicine, Orange, CA Jin Seok Ahn, Sungkyunkwan University School of Medicine Luigi De Petris, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden Ramaswamy Govindan, Washington University School of Medicine, St Louis, MO James Chih Hsin Yang, National Taiwan University, Taipei, Taiwan Brett Hughes, The Prince Charles Hospital, Chermside, and University of Queensland, Queensland, Australia Hervé Lena, Centre Hospitalier Universitaire de Rennes, Rennes Denis Moro Sibilot, Centre Hospitalier Universitaire de Grenoble, Institut National de la Santé et de la Recherche Médicale U823, Grenoble, France Alessandra Bearz, National Cancer Institute, Aviano, Italy Santiago Viteri Ramirez, Quiron Dexeus University Hospital, Barcelona, Spain Tarek Mekhail, Florida Hospital Cancer Institute, Orlando, FL Alexander Spira, Virginia Cancer Specialists, Fairfax, VA and Walter Bordogna, Bogdana Balas, Peter N Morcos
    J Clin Oncol 34:661-8. 2016
  6. doi Identification of a novel TMEM106B-ROS1 fusion variant in lung adenocarcinoma by comprehensive genomic profiling
    Sai Hong Ignatius Ou
    Chao Family Comprehensive Cancer Center, Department of Medicine, Division of Hematology Oncology, University of California Irvine School of Medicine, Orange, CA 92868, United States Electronic address
    Lung Cancer 88:352-4. 2015
  7. doi Radiation necrosis presenting as pseudoprogression (PsP) during alectinib treatment of previously radiated brain metastases in ALK-positive NSCLC: Implications for disease assessment and management
    Sai Hong Ignatius Ou
    Department of Medicine, Division of Hematology Oncology, University of California Irvine School of Medicine, Orange, CA 92868, United States Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, CA 92868, United States Electronic address
    Lung Cancer 88:355-9. 2015
  8. doi ALK F1174V mutation confers sensitivity while ALK I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progression
    Sai Hong Ou
    Department of Medicine, Division of Hematology Oncology, University of California Irvine School of Medicine, Orange, CA 92868, USA Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, CA 92868, USA Electronic address
    Lung Cancer 91:70-2. 2016
  9. doi Anaplastic Lymphoma Kinase (ALK) Signaling in Lung Cancer
    Sai Hong Ignatius Ou
    Chao Family Comprehensive Cancer Center, Department of Medicine, Division of Hematology Oncology, University of California Irvine School of Medicine, 101 City Drive, Bldg 56, RT81, Rm 241, Orange, CA, 92868, USA
    Adv Exp Med Biol 893:179-87. 2016
  10. doi I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib
    Sai Hong Ignatius Ou
    Department of Medicine, Division of Hematology Oncology, University of California Irvine School of Medicine, Orange, CA 92868, United States Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, CA 92868, United States Electronic address
    Lung Cancer 88:231-4. 2015

Detail Information

Publications58

  1. doi HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo- and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib
    Sai Hong Ignatius Ou
    Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, California Electronic address
    J Thorac Oncol . 2016
    ..Erb-b2 receptor tyrosine kinase (HER2) transmembrane domain (TMD) mutations (HER2V659E, HER2G660D) have previously been identified in lung adenocarcinomas, but their frequency and clinical significance is unknown...
  2. doi Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping
    Sai Hong Ignatius Ou
    Chao Family Comprehensive Cancer Center, Department of Medicine, Division of Hematology Oncology, University of California Irvine School of Medicine, Orange, California Electronic address
    J Thorac Oncol 12:137-140. 2017
    ..Preliminary clinical activity of crizotinib against METex14-positive NSCLC has been reported. The full spectrum of resistance mechanisms to crizotinib in METex14-positive NSCLC remains to be identified...
  3. doi High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression
    Sai Hong Ignatius Ou
    Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, CA 92868, USA Electronic address
    Lung Cancer 98:59-61. 2016
    ....
  4. doi Alectinib induced CNS radiation necrosis in an ALK+NSCLC patient with a remote (7 years) history of brain radiation
    Sai Hong Ignatius Ou
    Division of Hematology Oncology, Department of Medicine, University of California Irvine School of Medicine, Orange, CA 92868, United States Chao Family Comprehensive Cancer Center, Orange, CA 92868, United States Electronic address
    Lung Cancer 96:15-8. 2016
    ....
  5. doi Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study
    Sai Hong Ignatius Ou
    Sai Hong Ignatius Ou, University of California Irvine School of Medicine, Orange, CA Jin Seok Ahn, Sungkyunkwan University School of Medicine Luigi De Petris, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden Ramaswamy Govindan, Washington University School of Medicine, St Louis, MO James Chih Hsin Yang, National Taiwan University, Taipei, Taiwan Brett Hughes, The Prince Charles Hospital, Chermside, and University of Queensland, Queensland, Australia Hervé Lena, Centre Hospitalier Universitaire de Rennes, Rennes Denis Moro Sibilot, Centre Hospitalier Universitaire de Grenoble, Institut National de la Santé et de la Recherche Médicale U823, Grenoble, France Alessandra Bearz, National Cancer Institute, Aviano, Italy Santiago Viteri Ramirez, Quiron Dexeus University Hospital, Barcelona, Spain Tarek Mekhail, Florida Hospital Cancer Institute, Orlando, FL Alexander Spira, Virginia Cancer Specialists, Fairfax, VA and Walter Bordogna, Bogdana Balas, Peter N Morcos
    J Clin Oncol 34:661-8. 2016
    ..We investigated the efficacy and safety of alectinib, a potent and selective ALK inhibitor with excellent CNS penetration, in patients with crizotinib-refractory ALK-positive NSCLC...
  6. doi Identification of a novel TMEM106B-ROS1 fusion variant in lung adenocarcinoma by comprehensive genomic profiling
    Sai Hong Ignatius Ou
    Chao Family Comprehensive Cancer Center, Department of Medicine, Division of Hematology Oncology, University of California Irvine School of Medicine, Orange, CA 92868, United States Electronic address
    Lung Cancer 88:352-4. 2015
    ....
  7. doi Radiation necrosis presenting as pseudoprogression (PsP) during alectinib treatment of previously radiated brain metastases in ALK-positive NSCLC: Implications for disease assessment and management
    Sai Hong Ignatius Ou
    Department of Medicine, Division of Hematology Oncology, University of California Irvine School of Medicine, Orange, CA 92868, United States Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, CA 92868, United States Electronic address
    Lung Cancer 88:355-9. 2015
    ..Alectinib is a second generation ALK inhibitor that has significant CNS activity against brain metastases in anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC) patients...
  8. doi ALK F1174V mutation confers sensitivity while ALK I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progression
    Sai Hong Ou
    Department of Medicine, Division of Hematology Oncology, University of California Irvine School of Medicine, Orange, CA 92868, USA Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, CA 92868, USA Electronic address
    Lung Cancer 91:70-2. 2016
    ..This case report also validates the importance of developing structurally distinct ALK inhibitors for clinical use to overcome non-cross resistant ALK mutations. ..
  9. doi Anaplastic Lymphoma Kinase (ALK) Signaling in Lung Cancer
    Sai Hong Ignatius Ou
    Chao Family Comprehensive Cancer Center, Department of Medicine, Division of Hematology Oncology, University of California Irvine School of Medicine, 101 City Drive, Bldg 56, RT81, Rm 241, Orange, CA, 92868, USA
    Adv Exp Med Biol 893:179-87. 2016
    ..Understanding the ALK signaling pathway in lung cancer will likely provide the roadmap to the management of major epithelial malignancies driven by receptor tyrosine kinase rearrangement. ..
  10. doi I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib
    Sai Hong Ignatius Ou
    Department of Medicine, Division of Hematology Oncology, University of California Irvine School of Medicine, Orange, CA 92868, United States Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, CA 92868, United States Electronic address
    Lung Cancer 88:231-4. 2015
    ..Additionally one of these reports demonstrated one ALK+ NSCLC patient harboring an I1171T acquired mutation has responded to ceritinib, another second-generation ALK inhibitor...
  11. doi Heart rate decrease during crizotinib treatment and potential correlation to clinical response
    Sai Hong Ignatius Ou
    Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, CA, USA
    Cancer 119:1969-75. 2013
    ..We investigated the frequency and timing of SB, patient characteristics associated with SB during crizotinib treatment, and potential correlation between heart rate (HR) changes and clinical response to crizotinib...
  12. doi Asymptomatic profound sinus bradycardia (heart rate ≤45) in non-small cell lung cancer patients treated with crizotinib
    Sai Hong Ignatius Ou
    Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, California 92868 3298, USA
    J Thorac Oncol 6:2135-7. 2011
    ..Herein, we describe the clinical characteristics of three separate patients enrolled in the A8081001 trial (NCT00585195) who developed asymptomatic profound sinus bradycardia with their accompanying electrocardiogram tracings...
  13. pmc Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology
    Sai Hong Ignatius Ou
    Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, California 92868, USA
    Oncologist 17:1351-75. 2012
    ....
  14. doi ROS1 as a 'druggable' receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway
    Sai Hong Ignatius Ou
    Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, CA 92868, USA
    Expert Rev Anticancer Ther 12:447-56. 2012
    ..The next few years should witness a rapid pace of clinical research in ROS1-rearranged tumors utilizing available ALK inhibitors...
  15. doi Crizotinib: a drug that crystallizes a unique molecular subset of non-small-cell lung cancer
    Sai Hong Ignatius Ou
    Department of Medicine, Division of Hematology Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, 101 City Drive, Building 56, Orange, CA 92868, USA
    Expert Rev Anticancer Ther 12:151-62. 2012
    ..It took an unprecedented rapid 4 years from the publication of the discovery of ALK-rearranged NSCLC in August 2007 to the conditional approval of crizotinib in August 2011...
  16. ncbi Epidemiology of nasopharyngeal carcinoma in the United States: improved survival of Chinese patients within the keratinizing squamous cell carcinoma histology
    S Hi Ou
    Chao Family Comprehensive Cancer Center, Division of Hematology Oncology, Department of Medicine, School of Medicine, University of California, Irvine, USA
    Ann Oncol 18:29-35. 2007
    ..This study examined potential survival differences among nasopharyngeal carcinoma (NPC) patients from various ethnicities in the United States...
  17. pmc Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond
    Sai Hong Ignatius Ou
    Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, CA 92868, USA
    Drug Des Devel Ther 5:471-85. 2011
    ..It took an unprecedented four years from the discovery of ALK rearrangement in NSCLC to the approval of crizotinib, the first ever ALK inhibitor, for the treatment of ALK-rearranged NSCLC...
  18. doi Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification
    Sai Hong Ignatius Ou
    Division of Hematology Oncology, Department of Internal Medicine, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, California 92868 3298, USA
    J Thorac Oncol 6:942-6. 2011
    ..Here we report an NSCLC patient with de novo MET amplification but no ALK rearrangement who achieved a rapid and durable response to crizotinib indicating is also a bona fide MET inhibitor...
  19. doi Primary signet-ring carcinoma (SRC) of the lung: a population-based epidemiologic study of 262 cases with comparison to adenocarcinoma of the lung
    Sai Hong Ignatius Ou
    Chao Family Comprehensive Cancer Center, Division of Hematology Oncology, Department of Medicine, University of California, Irvine Medical Center, Orange, California 92868 3298, USA
    J Thorac Oncol 5:420-7. 2010
    ..We investigated the clinicopathologic features and survival outcome of primary signet-ring carcinoma (SRC) of the lung with comparison to adenocarcinoma of the lung...
  20. doi Rare subtypes of adenocarcinoma of the lung
    Sai Hong Ignatius Ou
    Department of Medicine, Division of Hematology Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, 101 City Drive, Building 56, Orange, CA 92868, USA
    Expert Rev Anticancer Ther 11:1535-42. 2011
    ..Rare variants of invasive adenocarcinoma of the lung will only now be classified from resection specimens where adequate architecture of tumor can be identified...
  21. doi A comparison study of clinicopathologic characteristics of Southern California Asian American Non-small Cell Lung Cancer (NSCLC) patients by smoking status
    Sai Hong Ignatius Ou
    Division of Hematology Oncology, Department of Medicine, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, California 92868 3298, USA
    J Thorac Oncol 5:158-68. 2010
    ..However, Asian ethnicity represents a diverse and heterogeneous population. In this report, we compared the clinicopathologic characteristics of Asian American NSCLC patient subgroups by smoking status...
  22. doi Carcinoma NOS is a common histologic diagnosis and is increasing in proportion among non-small cell lung cancer histologies
    Sai Hong Ignatius Ou
    Division of Hematology Oncology, Department of Medicine, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, California, USA
    J Thorac Oncol 4:1202-11. 2009
    ..We investigated whether the distribution of carcinoma NOS (not otherwise specified) among NSCLC cases in California have changed over time and determined the prognostic significance of carcinoma NOS...
  23. ncbi Prognostic significance of the non-size-based AJCC T2 descriptors: visceral pleura invasion, hilar atelectasis, or obstructive pneumonitis in stage IB non-small cell lung cancer is dependent on tumor size
    Sai Hong Ignatius Ou
    Chao Family Comprehensive Cancer Center, Division of Hematology Oncology, Department of Medicine, University of California Irvine Medical Center, Orange, CA 92868 3298, USA
    Chest 133:662-9. 2008
    ..The T2 descriptor for staging non-small cell lung cancer (NSCLC) contains several non-size-based criteria. It remains unknown whether the prognostic significance of these non-size-based criteria is dependent on tumor size...
  24. doi Asian ethnicity is a favorable prognostic factor for overall survival in non-small cell lung cancer (NSCLC) and is independent of smoking status
    Sai Hong Ignatius Ou
    Chao Family Comprehensive Cancer Center, Division of Hematology Oncology, Department of Medicine, University of Irvine Medical Center, Orange, California 92868 3298, USA
    J Thorac Oncol 4:1083-93. 2009
    ..Many Asian NSCLC patients were never-smokers, and never-smokers had improved survival than ever-smokers. We investigated whether Asian ethnicity is a favorable prognostic factor independent of smoking status...
  25. ncbi Prognostic factors for survival of stage I nonsmall cell lung cancer patients : a population-based analysis of 19,702 stage I patients in the California Cancer Registry from 1989 to 2003
    S H Ignatius Ou
    Division of Hematology Oncology, Department of Medicine, Chao Family Comprehensive Cancer Center, Orange, California 92868, USA
    Cancer 110:1532-41. 2007
    ....
  26. doi Prognostic significance of the number of lymph nodes removed at lobectomy in stage IA non-small cell lung cancer
    Sai Hong Ignatius Ou
    Chao Family Comprehensive Cancer Center, Division of Hematology Oncology, Department of Medicine, University of California Irvine Medical Center, Orange, CA 92868 3298, USA
    J Thorac Oncol 3:880-6. 2008
    ..We investigated whether the number of lymph nodes removed influences survival in stage IA NSCLC patients who underwent lobectomy...
  27. doi The applicability of the proposed IASLC staging revisions to small cell lung cancer (SCLC) with comparison to the current UICC 6th TNM Edition
    Sai Hong Ignatius Ou
    Chao Family Comprehensive Cancer Center, Division of Hematology Oncology, Department of Medicine, University of California Irvine Medical Center, Orange, CA 92868 3298, USA
    J Thorac Oncol 4:300-10. 2009
    ..We examined the impact of the proposed Internal Association for the Study of Lung Cancer (IASLC) tumor, node, metastasis (TNM) and stage grouping revisions on staging and survival outcome of small cell lung cancer (SCLC)...
  28. doi Prognostic factors for survival in extensive stage small cell lung cancer (ED-SCLC): the importance of smoking history, socioeconomic and marital statuses, and ethnicity
    Sai Hong Ignatius Ou
    Chao Family Comprehensive Cancer Center, Division of Hematology Oncology, Department of Medicine, University of California Irvine Medical Center, Orange, California, USA
    J Thorac Oncol 4:37-43. 2009
    ....
  29. doi Korean ethnicity as compared with white ethnicity is an independent favorable prognostic factor for overall survival in non-small cell lung cancer before and after the oral epidermal growth factor receptor tyrosine kinase inhibitor era
    Myung Ju Ahn
    Division of Hematology Oncology, Department of Internal Medicine, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, 101 The City Drive, Bldg 56, Rt 81, Rm 241, Orange, CA 92868, USA
    J Thorac Oncol 5:1185-96. 2010
    ..We have previously demonstrated, using a regional California Cancer Registry database, that Asian ethnicity is an independent favorable prognostic factor for overall survival (OS) in non-small cell lung cancer (NSCLC)...
  30. doi Validation study of the proposed IASLC staging revisions of the T4 and M non-small cell lung cancer descriptors using data from 23,583 patients in the California Cancer Registry
    Sai Hong Ignatius Ou
    Chao Family Comprehensive Cancer Center, Division of Hematology Oncology, Department of Medicine, University of Irvine Medical Center, Orange, California 92868, USA
    J Thorac Oncol 3:216-27. 2008
    ....
  31. pmc Factors associated with sinus bradycardia during crizotinib treatment: a retrospective analysis of two large-scale multinational trials (PROFILE 1005 and 1007)
    Sai Hong Ignatius Ou
    Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Irvine, California
    Cancer Med 5:617-22. 2016
    ..This is the first large-scale report investigating the association between treatment with a tyrosine kinase inhibitor and the development of bradycardia. HRs should be closely monitored during crizotinib treatment...
  32. doi Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib
    Sai Hong Ignatius Ou
    Division of Hematology Oncology, Department of Medicine, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, California Foundation Medicine, Inc, Cambridge, Massachusetts and Departmente of Pathology and Laboratory Medicine, Albany Medical Center, Albany, New York
    J Thorac Oncol 9:1821-5. 2014
    ....
  33. pmc Gastrointestinal malignancies harbor actionable MET exon 14 deletions
    Jeeyun Lee
    Department of Medicine, Division of Hematology Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
    Oncotarget 6:28211-22. 2015
    ..Substantial growth inhibition of METex14del+ patient tumor derived cell lines by several MET targeting drugs strongly suggests METex14del is a potential actionable driver mutation in GI malignancies. ..
  34. pmc ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer
    Justin F Gainor
    Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
    Clin Cancer Res 19:4273-81. 2013
    ..Recently, several case reports and small series have reported that ALK rearrangements can overlap with other oncogenic drivers in NSCLC in crizotinib-naïve and crizotinib-resistant cancers...
  35. pmc First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors
    Tianhong Li
    Division of Hematology Oncology, University of California Davis Comprehensive Cancer Center, 4501 X St 3016, Sacramento, CA, 95817, USA
    J Hematol Oncol 9:23. 2016
    ..This open-label, multicenter, first-in-human phase I study ( NCT01284192 ) assessed the safety, pharmacokinetic profile, and antitumor activity of ASP3026...
  36. pmc BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy
    Samuel J Klempner
    Division of Hematology Oncology, Department of Medicine, Chao Family Comprehensive Cancer Center, University of California, Irvine, School of Medicine, Orange, California
    Cancer Discov 6:594-600. 2016
    ..Our series represents the largest study of genomic profiling in colorectal neuroendocrine tumors and provides strong evidence that BRAF(V600E) is an oncogenic driver responsive to BRAF-MEK combination therapy in this molecular subset...
  37. ncbi Natural history of stage I non-small cell lung cancer: implications for early detection
    Dan J Raz
    University of California, San Francisco, 513 Parnassus Ave, S 321, San Francisco, CA 94131, USA
    Chest 132:193-9. 2007
    ..Our hypothesis is that long-term survival in patients with untreated stage I non-small cell lung cancer (NSCLC) is uncommon...
  38. pmc Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening
    Jeeyun Lee
    Department of Medicine, Division of Hematology Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
    Oncotarget 6:24320-32. 2015
    ..We investigated if immunohistochemistry (IHC) can be used to detect ALK rearrangement in gastrointestinal malignancies...
  39. doi Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial
    James Chih Hsin Yang
    Graduate Institute of Oncology and Cancer Research Centre, College of Medicine, National Taiwan University, Taipei, Taiwan
    Lancet Oncol 13:539-48. 2012
    ..Afatinib is an irreversible ErbB-family blocker with preclinical activity in non-small-cell lung cancer (NSCLC) with EGFR mutations. We aimed to assess the efficacy of afatinib in patients with lung adenocarcinoma and EGFR mutations...
  40. doi Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence
    Sai Hong Ignatius Ou
    Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Building 56, Room 241, RT81, Orange, CA 92868, USA
    Crit Rev Oncol Hematol 83:407-21. 2012
    ....
  41. doi The Clinical Use of Genomic Profiling to Distinguish Intrapulmonary Metastases From Synchronous Primaries in Non-Small-Cell Lung Cancer: A Mini-Review
    Samuel J Klempner
    Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Department of Medicine, Division of Hematology Oncology, University of California Irvine School of Medicine, Orange, CA Electronic address
    Clin Lung Cancer 16:334-339.e1. 2015
    ..Two cases are presented to highlight the potential immediate clinical implications of comprehensive genomic profiling. ..
  42. doi Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI
    Samuel J Klempner
    Division of Hematology Oncology, Department of Medicine, Chao Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, CA 92868, USA
    Lung Cancer 89:357-9. 2015
    ..However other resistance mechanisms remains to be discovered...
  43. pmc Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients
    Andrew J Weickhardt
    Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA
    Cancer 119:2383-90. 2013
    ..The detailed etiology of the effect, its symptomatic significance, and the effectiveness of subsequent testosterone replacement have not been previously reported...
  44. ncbi Survival improvements for advanced stage nonbronchioloalveolar carcinoma-type nonsmall cell lung cancer cases with ipsilateral intrapulmonary nodules
    Jason A Zell
    Division of Hematology Oncology, Department of Medicine, Chao Family Comprehensive Cancer Center, University of California at Irvine School of Medicine, Irvine, California 92697, USA
    Cancer 112:136-43. 2008
    ..However, it is not known whether these differences are observed in patients with non-BAC NSCLC...
  45. doi Low socioeconomic status is a poor prognostic factor for survival in stage I nonsmall cell lung cancer and is independent of surgical treatment, race, and marital status
    S H Ignatius Ou
    Chao Family Comprehensive Cancer Center, Division of Hematology Oncology, Department of Medicine, University of California Irvine Medical Center, Orange, CA 92868 3298, USA
    Cancer 112:2011-20. 2008
    ..In this study, the authors investigated the role of SES in this survival disparity among patients with stage I NSCLC...
  46. ncbi Epidemiology of bronchioloalveolar carcinoma: improvement in survival after release of the 1999 WHO classification of lung tumors
    Jason A Zell
    The Chao Family Comprehensive Cancer Center, Division of Hematology, Department of Medicine, University of California, Irvine, CA, USA
    J Clin Oncol 23:8396-405. 2005
    ..Classification changes for bronchioloalveolar carcinoma (BAC) by the WHO in May 1999 narrowed its definition. This study was undertaken in an attempt to characterize the impact of these changes on the epidemiology of BAC...
  47. doi TPD52L1-ROS1, a new ROS1 fusion variant in lung adenosquamous cell carcinoma identified by comprehensive genomic profiling
    Viola Weijia Zhu
    University Oncology Associates, Section of Hematology and Oncology, Department of Medicine, University of California, San Francisco Fresno, Fresno, CA 93701, United States Electronic address
    Lung Cancer 97:48-50. 2016
    ....
  48. ncbi Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer
    Shirish M Gadgeel
    Shirish M Gadgeel, Karmanos Cancer Institute, Wayne State University, Detroit, MI Alice T Shaw, Massachusetts General Hospital Leena Gandhi, Dana Farber Cancer Institute, Boston, MA Ramaswamy Govindan, Washington University School of Medicine, St Louis, MO Mark A Socinski, University of Pittsburgh, Pittsburgh, PA D Ross Camidge, University of Colorado Cancer Center, Denver, CO Alberto Chiappori, Thoracic Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL Sai Hong Ignatius Ou, University of California at Irvine, Orange, CA Luigi De Petris, Karolinska Institutet, Stockholm, Sweden Dong Wan Kim, Seoul National University Hospital, Seoul Ji Youn Han, Lung Cancer Centre, National Cancer Centre, Goyang, South Korea Denis L Moro Sibilot, Service de Pneumologie Michael Duruisseaux, Centre Hospitalier Universitaire de Grenoble, Grenoble Eric Dansin, Centre Oscar Lambret, Lille, France Lucio Crinò, Santa Maria della Misericordia Hospital,
    J Clin Oncol 34:4079-4085. 2016
    ..As previously reported, alectinib was well tolerated, regardless of baseline CNS disease. Conclusion Alectinib showed good efficacy against CNS metastases, in addition to systemic activity, in crizotinib-refractory ALK-positive NSCLC...
  49. doi Identification of ROS1 rearrangement in gastric adenocarcinoma
    Jeeyun Lee
    Department of Medicine, Division of Hematology Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
    Cancer 119:1627-35. 2013
    ..There is a need for the discovery of additional novel targets in GC...
  50. doi The central nervous system as a sanctuary site in ALK-positive non-small-cell lung cancer
    Justin F Gainor
    Departments of Medicine, Neurosurgery, Massachusetts General Hospital Cancer Center, Boston, Massachusetts and Department of Medicine, University of California, Irvine, Orange, California
    J Thorac Oncol 8:1570-3. 2013
    ....
  51. ncbi Capecitabine in advanced gastric or oesophagogastric cancer: a viewpoint by Sai-Hong Ignatius Ou and Randall F. Holcombe
    Sai Hong Ignatius Ou
    Division of Hematology Oncology, University of California, Irvine, Orange, California, USA
    Drugs 67:611-2. 2007
  52. doi Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer
    Sai Hong Ignatius Ou
    Chao Family Comprehensive Cancer Center, University of California at Irvine Medical Center, Orange, California Electronic address
    J Thorac Oncol 12:145-151. 2017
    ..This phase I trial was conducted to determine the safety, maximum tolerated dose (MTD)/recommended phase II dose, and efficacy of crizotinib plus erlotinib in patients with advanced NSCLC...
  53. pmc Molecular Testing for Treatment of Metastatic Non-Small Cell Lung Cancer: How to Implement Evidence-Based Recommendations
    Benjamin P Levy
    Mount Sinai Health Systems, New York, New York, USA Pfizer Oncology, New York, New York, USA Cone Health Cancer Center, Greensboro, North Carolina, USA Carolinas Pathology Group, Carolinas HealthCare System, Charlotte, North Carolina, USA Chao Family Comprehensive Cancer Center, University of California at Irvine School of Medicine, Orange, California, USA US Oncology Research, Ocala, Florida, USA Carolinas HealthCare System, Charlotte, North Carolina, USA The University of Texas MD Anderson Cancer Center, Houston, Texas, USA University of Colorado Cancer Center, Aurora, Colorado, USA
    Oncologist 20:1175-81. 2015
    ..We reviewed these challenges and established recommendations to help optimize tissue acquisition, processing, and testing within the framework of a multidisciplinary approach...
  54. doi Anaplastic lymphoma kinase inhibitors in brain metastases from ALK+ non-small cell lung cancer: hitting the target even in the CNS
    Samuel J Klempner
    Department of Medicine, Division of Hematology Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, CA 92868, USA
    Chin Clin Oncol 4:20. 2015
    ..The potential implications for TKI sequencing and important future research directions are discussed. ..
  55. pmc Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
    Sai Hong Ignatius Ou
    Chao Family Comprehensive Cancer Center, Division of Hematology Oncology, Department of Medicine, University of California, Irvine School of Medicine, Orange, CA, USA
    Drug Des Devel Ther 9:5641-53. 2015
    ....
  56. pmc Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies
    Siraj M Ali
    Foundation Medicine Inc, Cambridge, Massachusetts, USA Chao Family Comprehensive Cancer Center, Division of Hematology Oncology, Department of Medicine, University of California Irvine School of Medicine, Orange, California, USA Dana Farber Cancer Institute, Boston, Massachusetts, USA University of Chicago, Chicago, Illinois, USA Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, USA Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, New York, USA
    Oncologist 20:499-507. 2015
    ....
  57. doi Choroidal metastasis response to crizotinib in a ROS1-rearranged NSCLC patient
    Stephanie Lu
    Gavin Herbert Eye Institute, Department of Ophthalmology, University of California Irvine School of Medicine, Orange, CA 92868, United States
    Lung Cancer 87:207-9. 2015
    ..Similarly ROS1-rearranged NSCLC has very similar clinicopathologic characteristics as ALK-rearranged NSCLC and crizotinib has demonstrated significant clinical activity against ROS1-rearranged NSCLC...